| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis, Pulmonary | 38 | 2026 | 82 | 9.450 |
Why?
|
| Tuberculosis | 40 | 2025 | 255 | 7.660 |
Why?
|
| Mycobacterium tuberculosis | 45 | 2025 | 357 | 6.920 |
Why?
|
| Diabetes Mellitus | 19 | 2025 | 415 | 4.620 |
Why?
|
| Antitubercular Agents | 21 | 2026 | 73 | 3.280 |
Why?
|
| Macrophages | 13 | 2021 | 888 | 2.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2023 | 505 | 2.040 |
Why?
|
| Diabetes Complications | 8 | 2025 | 85 | 1.780 |
Why?
|
| Macrophages, Alveolar | 9 | 2016 | 33 | 1.630 |
Why?
|
| India | 16 | 2025 | 135 | 1.440 |
Why?
|
| Interleukin-16 | 16 | 2018 | 22 | 1.240 |
Why?
|
| Prediabetic State | 4 | 2024 | 45 | 1.230 |
Why?
|
| Cytokines | 17 | 2026 | 721 | 1.230 |
Why?
|
| Metformin | 6 | 2020 | 45 | 1.200 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2016 | 182 | 1.150 |
Why?
|
| Apoptosis | 8 | 2014 | 893 | 1.100 |
Why?
|
| Lymphocyte Activation | 9 | 2016 | 617 | 1.070 |
Why?
|
| Adaptive Immunity | 6 | 2025 | 78 | 1.030 |
Why?
|
| Inflammation | 8 | 2025 | 912 | 1.010 |
Why?
|
| Humans | 102 | 2026 | 40217 | 1.000 |
Why?
|
| HIV Infections | 12 | 2025 | 648 | 0.970 |
Why?
|
| Immune Evasion | 2 | 2017 | 45 | 0.960 |
Why?
|
| Mice | 39 | 2023 | 8809 | 0.940 |
Why?
|
| Neutrophils | 5 | 2018 | 307 | 0.930 |
Why?
|
| Biomarkers | 17 | 2024 | 945 | 0.910 |
Why?
|
| Animals | 53 | 2025 | 16893 | 0.910 |
Why?
|
| Comorbidity | 17 | 2025 | 717 | 0.890 |
Why?
|
| Adult | 44 | 2026 | 10255 | 0.880 |
Why?
|
| Lung | 14 | 2024 | 456 | 0.870 |
Why?
|
| Male | 42 | 2026 | 18271 | 0.770 |
Why?
|
| T-Lymphocyte Subsets | 6 | 2016 | 208 | 0.730 |
Why?
|
| Prospective Studies | 16 | 2026 | 1958 | 0.730 |
Why?
|
| Mice, Inbred C57BL | 18 | 2021 | 2708 | 0.720 |
Why?
|
| Hypercholesterolemia | 3 | 2012 | 58 | 0.720 |
Why?
|
| Interferon-gamma | 12 | 2019 | 459 | 0.710 |
Why?
|
| Mycobacterium bovis | 4 | 2013 | 26 | 0.710 |
Why?
|
| Disease Susceptibility | 8 | 2025 | 129 | 0.710 |
Why?
|
| Sirtuin 3 | 1 | 2021 | 8 | 0.700 |
Why?
|
| Tuberculosis Vaccines | 3 | 2017 | 21 | 0.660 |
Why?
|
| Apolipoproteins E | 3 | 2012 | 95 | 0.660 |
Why?
|
| Blood Glucose | 4 | 2023 | 401 | 0.650 |
Why?
|
| Latent Tuberculosis | 5 | 2022 | 17 | 0.640 |
Why?
|
| Immunity | 2 | 2017 | 85 | 0.640 |
Why?
|
| Mitochondria | 2 | 2021 | 298 | 0.610 |
Why?
|
| Mice, Knockout | 15 | 2018 | 1772 | 0.600 |
Why?
|
| Bacterial Load | 6 | 2019 | 24 | 0.600 |
Why?
|
| Nitric Oxide | 3 | 2024 | 124 | 0.580 |
Why?
|
| Middle Aged | 30 | 2026 | 10090 | 0.570 |
Why?
|
| Autophagy | 4 | 2016 | 192 | 0.570 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 192 | 0.550 |
Why?
|
| Phagocytosis | 3 | 2016 | 224 | 0.540 |
Why?
|
| CD4-Positive T-Lymphocytes | 10 | 2015 | 546 | 0.540 |
Why?
|
| Female | 39 | 2026 | 20392 | 0.530 |
Why?
|
| Cells, Cultured | 16 | 2016 | 1744 | 0.530 |
Why?
|
| Cohort Studies | 8 | 2024 | 1479 | 0.520 |
Why?
|
| Drug Discovery | 1 | 2017 | 64 | 0.520 |
Why?
|
| Klebsiella Infections | 1 | 2016 | 12 | 0.500 |
Why?
|
| Klebsiella pneumoniae | 1 | 2016 | 19 | 0.500 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 30 | 0.500 |
Why?
|
| Neutrophil Infiltration | 2 | 2018 | 47 | 0.490 |
Why?
|
| Malnutrition | 3 | 2025 | 37 | 0.470 |
Why?
|
| Dinoprostone | 1 | 2015 | 33 | 0.470 |
Why?
|
| Treatment Outcome | 12 | 2025 | 2863 | 0.460 |
Why?
|
| Hyperglycemia | 2 | 2016 | 92 | 0.450 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2015 | 72 | 0.450 |
Why?
|
| Protein Precursors | 4 | 2005 | 62 | 0.450 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2015 | 121 | 0.440 |
Why?
|
| Heterografts | 1 | 2013 | 46 | 0.420 |
Why?
|
| Receptors, Immunologic | 5 | 2016 | 166 | 0.400 |
Why?
|
| Sputum | 7 | 2022 | 20 | 0.390 |
Why?
|
| Antigens, Bacterial | 4 | 2024 | 177 | 0.380 |
Why?
|
| Obesity | 1 | 2019 | 970 | 0.380 |
Why?
|
| Smoking | 3 | 2025 | 584 | 0.380 |
Why?
|
| Receptors, LDL | 1 | 2012 | 26 | 0.370 |
Why?
|
| Immunity, Innate | 7 | 2025 | 662 | 0.370 |
Why?
|
| Microbial Viability | 1 | 2011 | 45 | 0.370 |
Why?
|
| Disease Models, Animal | 9 | 2019 | 1691 | 0.360 |
Why?
|
| Cell Communication | 1 | 2011 | 99 | 0.360 |
Why?
|
| Aged | 18 | 2025 | 8182 | 0.350 |
Why?
|
| Gene Expression | 4 | 2023 | 678 | 0.340 |
Why?
|
| Risk Factors | 10 | 2025 | 3141 | 0.340 |
Why?
|
| Signal Transduction | 7 | 2017 | 2581 | 0.330 |
Why?
|
| Hypoglycemic Agents | 3 | 2020 | 143 | 0.330 |
Why?
|
| Antibiotics, Antitubercular | 2 | 2019 | 4 | 0.330 |
Why?
|
| Chromatin | 1 | 2014 | 550 | 0.320 |
Why?
|
| Matrix Metalloproteinases | 2 | 2020 | 11 | 0.320 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2020 | 537 | 0.320 |
Why?
|
| Host-Pathogen Interactions | 4 | 2018 | 207 | 0.310 |
Why?
|
| Lung Injury | 2 | 2020 | 19 | 0.310 |
Why?
|
| Chemokines | 5 | 2024 | 63 | 0.300 |
Why?
|
| Cell Death | 3 | 2015 | 255 | 0.300 |
Why?
|
| Interleukin-1beta | 4 | 2019 | 236 | 0.290 |
Why?
|
| Mice, Obese | 2 | 2019 | 64 | 0.280 |
Why?
|
| Dendritic Cells | 3 | 2016 | 380 | 0.280 |
Why?
|
| Bronchoalveolar Lavage Fluid | 7 | 2018 | 45 | 0.270 |
Why?
|
| Cryptococcus neoformans | 2 | 2000 | 137 | 0.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2019 | 503 | 0.260 |
Why?
|
| Patient Compliance | 1 | 2008 | 222 | 0.260 |
Why?
|
| Retrospective Studies | 6 | 2022 | 3138 | 0.260 |
Why?
|
| Virulence | 4 | 2015 | 165 | 0.260 |
Why?
|
| HIV-1 | 6 | 2000 | 610 | 0.260 |
Why?
|
| BCG Vaccine | 4 | 2020 | 36 | 0.260 |
Why?
|
| HIV | 5 | 2024 | 53 | 0.250 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2026 | 5 | 0.250 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2016 | 145 | 0.250 |
Why?
|
| Monocytes | 2 | 2018 | 294 | 0.250 |
Why?
|
| Transcriptome | 3 | 2025 | 247 | 0.240 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2025 | 33 | 0.230 |
Why?
|
| Leukocytes | 1 | 2025 | 73 | 0.230 |
Why?
|
| CD4 Antigens | 5 | 2007 | 127 | 0.230 |
Why?
|
| Lung Diseases | 1 | 2026 | 88 | 0.230 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2013 | 202 | 0.230 |
Why?
|
| Necrosis | 4 | 2014 | 100 | 0.230 |
Why?
|
| Blood Platelets | 1 | 2025 | 85 | 0.220 |
Why?
|
| Family Characteristics | 1 | 2024 | 36 | 0.220 |
Why?
|
| Brazil | 3 | 2019 | 43 | 0.220 |
Why?
|
| Young Adult | 9 | 2024 | 2877 | 0.210 |
Why?
|
| Receptors, Interleukin-1 | 2 | 2016 | 63 | 0.210 |
Why?
|
| Streptozocin | 1 | 2023 | 21 | 0.210 |
Why?
|
| Glycerol | 1 | 2023 | 23 | 0.210 |
Why?
|
| Thrombosis | 1 | 2025 | 136 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2016 | 352 | 0.210 |
Why?
|
| Prevalence | 4 | 2026 | 870 | 0.200 |
Why?
|
| Chitinases | 1 | 2023 | 10 | 0.200 |
Why?
|
| Treatment Failure | 4 | 2025 | 119 | 0.200 |
Why?
|
| Mycobacterium Infections | 1 | 2003 | 14 | 0.200 |
Why?
|
| Phagosomes | 2 | 2014 | 39 | 0.200 |
Why?
|
| Thymus Gland | 2 | 2014 | 215 | 0.190 |
Why?
|
| Lymph Nodes | 3 | 2018 | 160 | 0.190 |
Why?
|
| Chemokines, CC | 1 | 2002 | 4 | 0.190 |
Why?
|
| Antigen-Presenting Cells | 2 | 2014 | 150 | 0.190 |
Why?
|
| Caspases | 2 | 2006 | 144 | 0.190 |
Why?
|
| Acute-Phase Proteins | 1 | 2021 | 29 | 0.180 |
Why?
|
| Flow Cytometry | 6 | 2015 | 539 | 0.180 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 832 | 0.180 |
Why?
|
| Lipopolysaccharides | 3 | 2012 | 560 | 0.180 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2020 | 2 | 0.170 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 26 | 0.170 |
Why?
|
| Immunophenotyping | 3 | 2016 | 151 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 90 | 0.170 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2021 | 205 | 0.170 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2020 | 8 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 443 | 0.170 |
Why?
|
| S100A12 Protein | 1 | 2019 | 1 | 0.160 |
Why?
|
| Gene Expression Regulation | 5 | 2018 | 1340 | 0.160 |
Why?
|
| Reactive Oxygen Species | 1 | 2021 | 185 | 0.160 |
Why?
|
| Interleukin-6 | 4 | 2024 | 238 | 0.160 |
Why?
|
| Eicosanoids | 1 | 2019 | 23 | 0.160 |
Why?
|
| Case-Control Studies | 4 | 2025 | 664 | 0.160 |
Why?
|
| Disease Management | 2 | 2017 | 127 | 0.160 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2021 | 321 | 0.160 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2019 | 13 | 0.160 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 86 | 0.150 |
Why?
|
| Asthma | 5 | 2007 | 267 | 0.150 |
Why?
|
| Cell Movement | 5 | 2010 | 329 | 0.150 |
Why?
|
| Glucose Tolerance Test | 2 | 2016 | 89 | 0.150 |
Why?
|
| Cathepsins | 2 | 2011 | 29 | 0.150 |
Why?
|
| Microscopy, Confocal | 3 | 2016 | 197 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2019 | 178 | 0.150 |
Why?
|
| Prognosis | 4 | 2023 | 921 | 0.150 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2018 | 2 | 0.150 |
Why?
|
| Proteome | 2 | 2017 | 103 | 0.140 |
Why?
|
| Airway Remodeling | 1 | 2018 | 2 | 0.140 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 149 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 168 | 0.140 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2018 | 61 | 0.140 |
Why?
|
| alpha-Defensins | 1 | 2017 | 1 | 0.140 |
Why?
|
| Respiration | 1 | 2018 | 49 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 130 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2020 | 651 | 0.140 |
Why?
|
| Pneumonia | 1 | 2018 | 95 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 5 | 2011 | 688 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 3 | 2018 | 463 | 0.140 |
Why?
|
| HIV Envelope Protein gp120 | 4 | 1995 | 118 | 0.140 |
Why?
|
| Cysteine Endopeptidases | 1 | 1998 | 87 | 0.140 |
Why?
|
| Computational Biology | 2 | 2017 | 262 | 0.130 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2017 | 52 | 0.130 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 20 | 0.130 |
Why?
|
| Adipose Tissue | 1 | 2019 | 241 | 0.130 |
Why?
|
| Adipocytes | 1 | 2019 | 234 | 0.130 |
Why?
|
| Energy Metabolism | 1 | 2019 | 322 | 0.130 |
Why?
|
| Angiogenic Proteins | 1 | 2016 | 3 | 0.130 |
Why?
|
| Respiratory Hypersensitivity | 2 | 2007 | 9 | 0.130 |
Why?
|
| Bone Marrow Cells | 2 | 2014 | 194 | 0.130 |
Why?
|
| Research Design | 1 | 2019 | 419 | 0.130 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 663 | 0.130 |
Why?
|
| Epitopes | 2 | 2007 | 263 | 0.130 |
Why?
|
| South Africa | 3 | 2021 | 10 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 2 | 2016 | 194 | 0.130 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2016 | 2 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1998 | 229 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2024 | 142 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2019 | 370 | 0.120 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2016 | 135 | 0.120 |
Why?
|
| Bacterial Proteins | 2 | 2014 | 668 | 0.120 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2015 | 7 | 0.120 |
Why?
|
| Models, Immunological | 2 | 2013 | 73 | 0.120 |
Why?
|
| Mannose | 2 | 2012 | 21 | 0.120 |
Why?
|
| Chemotaxis, Leukocyte | 4 | 2012 | 55 | 0.120 |
Why?
|
| Proteomics | 1 | 2017 | 196 | 0.120 |
Why?
|
| Public Health | 1 | 2017 | 131 | 0.120 |
Why?
|
| Insulin | 1 | 2019 | 616 | 0.120 |
Why?
|
| Killer Cells, Natural | 1 | 2016 | 166 | 0.120 |
Why?
|
| Membrane Glycoproteins | 2 | 2016 | 586 | 0.120 |
Why?
|
| omega-N-Methylarginine | 1 | 2015 | 2 | 0.120 |
Why?
|
| Indomethacin | 1 | 2015 | 16 | 0.120 |
Why?
|
| Quinolines | 1 | 2015 | 28 | 0.120 |
Why?
|
| Imidazoles | 1 | 2015 | 51 | 0.110 |
Why?
|
| Ovalbumin | 1 | 2015 | 96 | 0.110 |
Why?
|
| Interferon-gamma Release Tests | 3 | 2022 | 6 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2015 | 88 | 0.110 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2014 | 1 | 0.110 |
Why?
|
| Tuberculosis, Pleural | 1 | 2014 | 1 | 0.110 |
Why?
|
| Perforin | 1 | 2014 | 24 | 0.110 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2014 | 18 | 0.110 |
Why?
|
| Chemokine CXCL9 | 1 | 2014 | 22 | 0.110 |
Why?
|
| Interleukin-2 | 1 | 2015 | 158 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 532 | 0.110 |
Why?
|
| Chemokine CXCL10 | 1 | 2014 | 43 | 0.110 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 562 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 125 | 0.110 |
Why?
|
| Cell Migration Inhibition | 2 | 2012 | 7 | 0.110 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2013 | 76 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 240 | 0.100 |
Why?
|
| T-Lymphocytes | 4 | 2007 | 828 | 0.100 |
Why?
|
| Species Specificity | 3 | 1999 | 273 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2018 | 535 | 0.100 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 1074 | 0.100 |
Why?
|
| Mice, SCID | 1 | 2013 | 455 | 0.100 |
Why?
|
| Risk | 1 | 2013 | 248 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 53 | 0.100 |
Why?
|
| ADAM Proteins | 1 | 2012 | 26 | 0.100 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 489 | 0.100 |
Why?
|
| Th1 Cells | 1 | 2012 | 110 | 0.100 |
Why?
|
| AIDS-Related Complex | 1 | 1992 | 3 | 0.090 |
Why?
|
| Caspase 3 | 2 | 2006 | 86 | 0.090 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2011 | 7 | 0.090 |
Why?
|
| Phenotype | 1 | 2014 | 823 | 0.090 |
Why?
|
| Green Fluorescent Proteins | 2 | 2011 | 336 | 0.090 |
Why?
|
| Coculture Techniques | 1 | 2011 | 73 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2012 | 58 | 0.090 |
Why?
|
| Interleukin-18 | 1 | 2011 | 64 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2011 | 53 | 0.090 |
Why?
|
| Heart Transplantation | 1 | 2011 | 57 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1992 | 102 | 0.090 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2011 | 11 | 0.090 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2011 | 20 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 36 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2012 | 638 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 106 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2011 | 173 | 0.090 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2011 | 94 | 0.090 |
Why?
|
| Tropheryma | 1 | 2010 | 1 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 110 | 0.090 |
Why?
|
| ROC Curve | 2 | 2021 | 176 | 0.090 |
Why?
|
| RNA, Messenger | 6 | 2008 | 1254 | 0.090 |
Why?
|
| Recurrence | 2 | 2022 | 364 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 200 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2021 | 58 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2011 | 145 | 0.080 |
Why?
|
| Cell Line | 4 | 2018 | 1697 | 0.080 |
Why?
|
| Macrophage Colony-Stimulating Factor | 2 | 2023 | 28 | 0.080 |
Why?
|
| Macrophage Activation | 1 | 2010 | 106 | 0.080 |
Why?
|
| Lysosomes | 1 | 2011 | 138 | 0.080 |
Why?
|
| Cell Nucleus | 2 | 2005 | 574 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 215 | 0.080 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 403 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 278 | 0.080 |
Why?
|
| Recombinant Proteins | 3 | 2006 | 582 | 0.080 |
Why?
|
| Adolescent | 3 | 2024 | 4034 | 0.080 |
Why?
|
| Cell Cycle | 4 | 2005 | 352 | 0.080 |
Why?
|
| Self Tolerance | 1 | 2009 | 17 | 0.080 |
Why?
|
| Vaccinia | 1 | 2009 | 31 | 0.080 |
Why?
|
| Retroviridae Proteins | 1 | 1988 | 2 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2011 | 732 | 0.080 |
Why?
|
| Annexins | 1 | 2008 | 5 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2019 | 290 | 0.070 |
Why?
|
| Vaccinia virus | 1 | 2009 | 66 | 0.070 |
Why?
|
| Toll-Like Receptors | 2 | 2011 | 393 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2012 | 1116 | 0.070 |
Why?
|
| Lung Abscess | 1 | 2008 | 5 | 0.070 |
Why?
|
| Viral Envelope Proteins | 1 | 1988 | 72 | 0.070 |
Why?
|
| Colony Count, Microbial | 1 | 2008 | 46 | 0.070 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1988 | 85 | 0.070 |
Why?
|
| Rifampin | 1 | 2008 | 22 | 0.070 |
Why?
|
| Isoniazid | 1 | 2008 | 11 | 0.070 |
Why?
|
| Granulocytes | 1 | 2008 | 58 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2009 | 250 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 597 | 0.070 |
Why?
|
| Receptors, Histamine | 1 | 2007 | 1 | 0.070 |
Why?
|
| Mice, Inbred ICR | 1 | 2007 | 26 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2008 | 342 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2019 | 253 | 0.070 |
Why?
|
| Spleen | 1 | 2008 | 391 | 0.070 |
Why?
|
| HLA Antigens | 1 | 2007 | 36 | 0.070 |
Why?
|
| Transcription Factors | 2 | 2012 | 1328 | 0.070 |
Why?
|
| Amino Acid Sequence | 3 | 1999 | 1416 | 0.070 |
Why?
|
| Molecular Sequence Data | 3 | 1999 | 1766 | 0.060 |
Why?
|
| Calcium | 2 | 2006 | 497 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2007 | 86 | 0.060 |
Why?
|
| Leukocyte Count | 2 | 2025 | 72 | 0.060 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2007 | 156 | 0.060 |
Why?
|
| Caspase Inhibitors | 1 | 2006 | 17 | 0.060 |
Why?
|
| Chelating Agents | 1 | 2006 | 45 | 0.060 |
Why?
|
| Arteriolosclerosis | 1 | 2005 | 1 | 0.060 |
Why?
|
| Phagocytes | 1 | 2006 | 49 | 0.060 |
Why?
|
| Collateral Circulation | 1 | 2005 | 20 | 0.060 |
Why?
|
| Interleukin-13 | 1 | 2006 | 25 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2007 | 463 | 0.060 |
Why?
|
| Interleukin-17 | 2 | 2019 | 65 | 0.060 |
Why?
|
| Allergens | 1 | 2006 | 36 | 0.060 |
Why?
|
| Georgia | 1 | 2026 | 79 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2005 | 25 | 0.060 |
Why?
|
| Transfection | 2 | 2005 | 592 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1668 | 0.060 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2005 | 9 | 0.060 |
Why?
|
| Blood Cell Count | 1 | 2025 | 31 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 2 | 1999 | 64 | 0.060 |
Why?
|
| Genotype | 2 | 2016 | 444 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 870 | 0.060 |
Why?
|
| Membrane Potentials | 1 | 2005 | 116 | 0.060 |
Why?
|
| Calcineurin | 1 | 2005 | 35 | 0.060 |
Why?
|
| Ischemia | 1 | 2005 | 129 | 0.060 |
Why?
|
| Chemotactic Factors | 3 | 1995 | 21 | 0.060 |
Why?
|
| Chemokine CCL5 | 2 | 2002 | 27 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 159 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 364 | 0.050 |
Why?
|
| Tryptophan Oxygenase | 1 | 2023 | 1 | 0.050 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 3 | 0.050 |
Why?
|
| Walk Test | 1 | 2023 | 3 | 0.050 |
Why?
|
| Respiratory Tract Diseases | 1 | 2003 | 27 | 0.050 |
Why?
|
| Respiratory System | 1 | 2003 | 25 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2003 | 59 | 0.050 |
Why?
|
| Lymphocyte Count | 2 | 2015 | 60 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 410 | 0.050 |
Why?
|
| Hypersensitivity | 1 | 2003 | 40 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 43 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 110 | 0.050 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2002 | 8 | 0.050 |
Why?
|
| Chemokine CCL4 | 1 | 2002 | 11 | 0.050 |
Why?
|
| Serum Amyloid P-Component | 1 | 2021 | 1 | 0.050 |
Why?
|
| Pregnancy-Associated alpha 2-Macroglobulins | 1 | 2021 | 1 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2026 | 663 | 0.050 |
Why?
|
| Haptoglobins | 1 | 2021 | 9 | 0.050 |
Why?
|
| COS Cells | 2 | 2001 | 152 | 0.050 |
Why?
|
| Infant | 1 | 2024 | 989 | 0.040 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2021 | 11 | 0.040 |
Why?
|
| Vital Capacity | 1 | 2021 | 21 | 0.040 |
Why?
|
| Spirometry | 1 | 2021 | 24 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2021 | 36 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 133 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2024 | 1203 | 0.040 |
Why?
|
| Guinea Pigs | 1 | 2020 | 77 | 0.040 |
Why?
|
| CD8 Antigens | 2 | 2005 | 47 | 0.040 |
Why?
|
| Gene Products, tat | 2 | 1997 | 10 | 0.040 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2020 | 58 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2020 | 73 | 0.040 |
Why?
|
| HMGB1 Protein | 1 | 2019 | 18 | 0.040 |
Why?
|
| Glycation End Products, Advanced | 1 | 2019 | 16 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 32 | 0.040 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2012 | 241 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 99 | 0.040 |
Why?
|
| Interleukin-1alpha | 1 | 2019 | 21 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 528 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 585 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 698 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 330 | 0.040 |
Why?
|
| Biopsy | 1 | 2019 | 228 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 138 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 96 | 0.040 |
Why?
|
| Terpenes | 1 | 2018 | 18 | 0.040 |
Why?
|
| Lymphokines | 2 | 1995 | 61 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 62 | 0.040 |
Why?
|
| Epithelium | 1 | 2018 | 75 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2018 | 36 | 0.040 |
Why?
|
| Concanavalin A | 1 | 1998 | 38 | 0.040 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 1998 | 31 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 48 | 0.040 |
Why?
|
| beta-Defensins | 1 | 2017 | 1 | 0.030 |
Why?
|
| Cathelicidins | 1 | 2017 | 9 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 2 | 2009 | 95 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1998 | 118 | 0.030 |
Why?
|
| Endothelium, Vascular | 2 | 1997 | 132 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2017 | 99 | 0.030 |
Why?
|
| Binding Sites | 1 | 1999 | 791 | 0.030 |
Why?
|
| Child | 1 | 2024 | 2856 | 0.030 |
Why?
|
| Cyclosporine | 2 | 2009 | 53 | 0.030 |
Why?
|
| HIV Long Terminal Repeat | 1 | 1997 | 11 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 1997 | 27 | 0.030 |
Why?
|
| Lymphocytes | 3 | 1997 | 153 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2016 | 1 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 8 | 0.030 |
Why?
|
| Animals, Outbred Strains | 1 | 2016 | 7 | 0.030 |
Why?
|
| Lipoproteins | 1 | 1997 | 69 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2016 | 15 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 1165 | 0.030 |
Why?
|
| Fasting | 1 | 2016 | 36 | 0.030 |
Why?
|
| Receptors, Interferon | 1 | 2016 | 14 | 0.030 |
Why?
|
| HIV Antibodies | 1 | 1997 | 123 | 0.030 |
Why?
|
| Homeostasis | 2 | 2016 | 305 | 0.030 |
Why?
|
| Succinimides | 1 | 1995 | 17 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 1995 | 18 | 0.030 |
Why?
|
| Models, Molecular | 1 | 1999 | 965 | 0.030 |
Why?
|
| Research | 1 | 2017 | 161 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 74 | 0.030 |
Why?
|
| Rats | 2 | 1996 | 1616 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2017 | 237 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 148 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1997 | 368 | 0.030 |
Why?
|
| Mutation | 1 | 2022 | 2123 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2016 | 269 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2015 | 179 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1995 | 97 | 0.030 |
Why?
|
| Protein Binding | 2 | 2016 | 1385 | 0.030 |
Why?
|
| Bronchitis | 1 | 1994 | 17 | 0.030 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 1994 | 1 | 0.030 |
Why?
|
| CD3 Complex | 1 | 1994 | 58 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 290 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2016 | 250 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 520 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 460 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 773 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 813 | 0.030 |
Why?
|
| Bronchogenic Cyst | 1 | 1993 | 1 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 1993 | 39 | 0.030 |
Why?
|
| Mass Screening | 1 | 2017 | 409 | 0.030 |
Why?
|
| Protein Modification, Translational | 1 | 2012 | 6 | 0.020 |
Why?
|
| ADAM17 Protein | 1 | 2012 | 8 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1055 | 0.020 |
Why?
|
| CD24 Antigen | 1 | 2012 | 14 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 39 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2012 | 127 | 0.020 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 1992 | 6 | 0.020 |
Why?
|
| HIV Antigens | 1 | 1992 | 17 | 0.020 |
Why?
|
| Gene Products, env | 1 | 1992 | 13 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2011 | 8 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1992 | 45 | 0.020 |
Why?
|
| Fetus | 1 | 2012 | 78 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 329 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 166 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2012 | 213 | 0.020 |
Why?
|
| Antibodies | 1 | 2011 | 151 | 0.020 |
Why?
|
| NADPH Oxidase 2 | 1 | 2011 | 34 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2011 | 61 | 0.020 |
Why?
|
| Sirolimus | 1 | 2011 | 59 | 0.020 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2011 | 77 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 795 | 0.020 |
Why?
|
| Lymphotoxin-alpha | 1 | 2009 | 7 | 0.020 |
Why?
|
| Splenectomy | 1 | 2009 | 28 | 0.020 |
Why?
|
| Aerosols | 1 | 2009 | 35 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 218 | 0.020 |
Why?
|
| Endocytosis | 1 | 2010 | 134 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 352 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2009 | 15 | 0.020 |
Why?
|
| Inflammasomes | 1 | 2012 | 305 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2009 | 31 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1069 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2009 | 39 | 0.020 |
Why?
|
| United States | 1 | 2019 | 4886 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2009 | 117 | 0.020 |
Why?
|
| Inositol Phosphates | 1 | 1988 | 14 | 0.020 |
Why?
|
| Receptors, HIV | 1 | 1988 | 14 | 0.020 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 1988 | 27 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2009 | 123 | 0.020 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2009 | 88 | 0.020 |
Why?
|
| Receptors, Virus | 1 | 1988 | 46 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 244 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2009 | 54 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 173 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1988 | 400 | 0.020 |
Why?
|
| Information Systems | 1 | 2007 | 26 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2007 | 42 | 0.020 |
Why?
|
| Receptors, Histamine H4 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Methylhistamines | 1 | 2007 | 1 | 0.020 |
Why?
|
| Histamine | 1 | 2007 | 20 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 18 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2009 | 246 | 0.020 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 2 | 1997 | 10 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2001 | 428 | 0.020 |
Why?
|
| Ambrosia | 1 | 2006 | 1 | 0.020 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2006 | 2 | 0.020 |
Why?
|
| Pollen | 1 | 2006 | 5 | 0.020 |
Why?
|
| Interleukin-5 | 1 | 2006 | 30 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2005 | 44 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2007 | 152 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2006 | 119 | 0.020 |
Why?
|
| Software | 1 | 2007 | 282 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 448 | 0.010 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2005 | 7 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2005 | 25 | 0.010 |
Why?
|
| Internet | 1 | 2007 | 338 | 0.010 |
Why?
|
| Immune System | 1 | 2005 | 111 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 497 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 258 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 282 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 456 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2008 | 730 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 673 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 268 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2001 | 101 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2001 | 120 | 0.010 |
Why?
|
| Protein Transport | 1 | 2001 | 348 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2000 | 582 | 0.010 |
Why?
|
| Bronchoalveolar Lavage | 1 | 1997 | 3 | 0.010 |
Why?
|
| Cell Count | 1 | 1997 | 106 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1997 | 172 | 0.010 |
Why?
|
| HIV Reverse Transcriptase | 1 | 1997 | 8 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1997 | 16 | 0.010 |
Why?
|
| Virus Latency | 1 | 1997 | 25 | 0.010 |
Why?
|
| Glycine | 1 | 1997 | 34 | 0.010 |
Why?
|
| Virus Activation | 1 | 1997 | 18 | 0.010 |
Why?
|
| Biological Transport | 1 | 1997 | 255 | 0.010 |
Why?
|
| Chemotaxis | 1 | 1995 | 37 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 1995 | 75 | 0.010 |
Why?
|
| Rifabutin | 1 | 1995 | 3 | 0.010 |
Why?
|
| Quinones | 1 | 1995 | 5 | 0.010 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 1995 | 7 | 0.010 |
Why?
|
| Virus Replication | 1 | 1997 | 248 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1997 | 351 | 0.010 |
Why?
|
| Benzoquinones | 1 | 1995 | 12 | 0.010 |
Why?
|
| Lactams, Macrocyclic | 1 | 1995 | 23 | 0.010 |
Why?
|
| Antigens | 1 | 1995 | 126 | 0.010 |
Why?
|
| NF-kappa B | 1 | 1997 | 366 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1994 | 18 | 0.010 |
Why?
|
| Immunocompetence | 1 | 1994 | 17 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 1994 | 23 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 1994 | 61 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 164 | 0.010 |
Why?
|
| Cell Separation | 1 | 1994 | 124 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1994 | 109 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1997 | 656 | 0.010 |
Why?
|
| Cattle | 1 | 1994 | 264 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1994 | 133 | 0.010 |
Why?
|
| Thoracotomy | 1 | 1993 | 15 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 1993 | 20 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1995 | 803 | 0.010 |
Why?
|
| Kinetics | 1 | 1994 | 679 | 0.010 |
Why?
|
| Radiography | 1 | 1993 | 273 | 0.010 |
Why?
|
| Time Factors | 1 | 1995 | 2422 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1988 | 19 | 0.000 |
Why?
|
| Second Messenger Systems | 1 | 1988 | 25 | 0.000 |
Why?
|
| Cytological Techniques | 1 | 1988 | 17 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1988 | 441 | 0.000 |
Why?
|